Form 4: Vaxcyte Director Acquires Shares and Options

Vaxcyte, Inc. reports that Director Olivier Brandicourt acquired 2,194 shares of common stock and was granted options for 11,034 shares.

Summary

• Director Olivier Brandicourt acquired 2,194 shares of Vaxcyte, Inc. common stock on June 15, 2026.
• These shares were acquired as part of the vesting of restricted stock units (RSUs).
• Additionally, Mr. Brandicourt was granted stock options to purchase 11,034 shares of common stock at an exercise price of $49.56.
• The RSUs are set to fully vest on June 15, 2027, or the day before the next annual stockholder meeting, whichever comes first, contingent on continued service.
• The stock options will also fully vest by June 15, 2027, or the day before the next annual stockholder meeting, subject to acceleration and continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to executive compensation rather than significant operational or financial performance updates.

Positives

• Director Olivier Brandicourt's acquisition of shares and options indicates continued commitment and investment in the company.
• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term value creation.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continuous service through the vesting date, implying a risk of forfeiture if service is terminated.
• The exercise price of the stock options ($49.56) is significantly higher than the current market price, suggesting that the options may not be immediately in-the-money.

Future Outlook

The vesting schedule for both RSUs and stock options is tied to specific future dates (June 15, 2027, or the day prior to the next annual meeting), indicating a forward-looking compensation structure contingent on continued employment and company performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the biotechnology and pharmaceutical sectors as a means of executive compensation and aligning incentives. The details of the stock option grant and RSU vesting provide insight into Vaxcyte's compensation strategy for its leadership.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance through options can be viewed positively, as it incentivizes value creation. However, the immediate impact on share price is likely minimal.
• Employees: This filing highlights a standard compensation practice for directors, which may indirectly influence overall employee compensation strategies.
• Management: Reinforces the use of equity-based compensation as a tool for retaining key leadership.

Next Steps

• Continued service by Olivier Brandicourt through June 15, 2027, or the day prior to the next annual meeting, for full vesting of RSUs and stock options.
• Potential exercise of stock options by Olivier Brandicourt after vesting, subject to market conditions and personal financial decisions.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership, Securities Exchange Act